PATIENT ALERT: Information regarding COVID-19. 

Clinical Research & Trials

USO 17188

A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK3475-KN756)

 

Disease Types: Breast Cancer Research

Eligibility Requirements:

-ER+/HER 2-  grade 3 localized invasive ductal breast adenocarcinoma T1c-T2, cN1-cN2 or T3-T4, cNo-cN2
-No: bilateral, metastatic, or multi-centric breast cancer; prior excisional biopsy of primary tumor or axillary lymph nodes or sentinel lymph node biopsy; history of non-infectious pneumonitis requiring treatment with steroids or current pneumonitis; 
immunodeficiency or condition requiring chronic steroid therapy; known active TB or Hep C or known history of HIV or Hep B

Available at: